ArticleEuropean urology open science2026
Evaluation of the Patient Acceptability of Automated Communication of Prostate-specific Antigen Results After Local Treatment for Prostate Cancer.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) monitoring is the cornerstone of prostate cancer (PC) follow-up after radical prostatectomy (RP) and radiotherapy (RT). St. Antonius Hospital (Nieuwegein/Utrecht, The Netherlands) launched the Automatic PSA Project in 2022 for automated digital communication of PSA results. PSA results are reviewed by a clinical team, and stable results are sent via automated messages; while rising PSA prompts referral to a urologist. Automated digital communication of PSA results reduces clinician and outpatient workloads and costs and patient travel. We evaluated the patient acceptability of this approach using the Service User Technology Acceptability Questionnaire. Eligible patients had undergone RP or RT, had stable PSA levels 6 mo after treatment, and had access to the patient portal. Participation was voluntary and limited to men without significant functional symptoms. Between January 2023 and September 2024, 100/325 participants in the project completed the questionnaire. Most men were aged ≥65 yr, had moderate to high digital skills, and had undergone RP (91%). Overall acceptability was high (median score 5.27, interquartile range 4.98-5.75), 72% considered digital PSA communication a suitable replacement, and 95% regarded it as a valuable addition to standard care. Privacy concerns were low. Selection bias could not be ruled out. Digital PSA communication appears to be acceptable and sustainable for selected patients, supporting broader implementation in future PC care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.